유전체학 서비스 시장 기회, 성장 촉진요인, 산업 동향 분석, 예측(2025-2034년)

The Global Genomics Services Market, valued at USD 8.5 billion in 2024, is projected to grow at a CAGR of 11.5% from 2025 to 2034. The market is expanding due to the increasing prevalence of genetic disorders and the rising emphasis on personalized medicine. As the understanding of genetics deepens, the demand for genomic services is surging, particularly with the growing integration of precision medicine in treatment protocols. The global healthcare landscape is witnessing a shift toward more personalized approaches driven by advancements in genetic testing and gene sequencing technologies. These developments are paving the way for early diagnosis, targeted treatments, and improved patient outcomes. Governments and private organizations worldwide are investing heavily in genomic research, with an increasing focus on enhancing diagnostic accuracy and developing new therapies. As precision medicine gains traction, genomic services are becoming indispensable in research, clinical diagnostics, and therapeutic development, positioning the market for significant growth over the next decade.

The development of cutting-edge technologies, including next-generation sequencing (NGS), is a critical driver propelling the genomics services market forward. Biotechnology startups and established industry leaders are actively investing in research and development to refine these technologies and enhance their capabilities. The declining cost of sequencing has further accelerated the adoption of NGS, allowing researchers and clinicians to sequence DNA and RNA quickly and accurately. This technology can identify gene mutations or variations in a fraction of the time compared to traditional methods, making it a preferred choice in both research and clinical diagnostics. In 2023, the next-generation sequencing segment alone generated USD 2.7 billion, underscoring its pivotal role in advancing genomic research and personalized medicine. Additionally, other prominent service types include genotyping, microarrays, and Sanger sequencing, each contributing to the market's growth by offering specialized solutions tailored to different research and clinical needs.

The genomics services market is divided between research and diagnostics, with the research segment accounting for 63.6% of the market share in 2024. The increasing investments from both government and private sectors in genomic research are driving the growth of this segment. Academic institutions and biotechnology companies are leveraging genomic services to study gene structure, function, and variation, facilitating the discovery of novel therapies and improving the understanding of genetic disorders. The rapid adoption of genomics in drug discovery and clinical research highlights the growing importance of genomic services in transforming modern healthcare.

The U.S. Genomics Services Market is also expected to witness robust growth, maintaining a CAGR of 11.5% through 2034. This growth is fueled by substantial government funding for genomic research, the availability of advanced research facilities, and increasing public awareness of precision medicine. The United States continues to lead the global genomics landscape, with its well-established infrastructure and strong collaborations between public and private entities contributing to the rapid advancement of genomic services. The growing emphasis on genomic research and the integration of precision medicine into clinical workflows reinforce the significance of genomics in healthcare and drug development, positioning the market for sustained growth in the coming years.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360⁰ synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Technological advancements in genomics
    • 3.2.1.2 Rising prevalence of genetic disorders
    • 3.2.1.3 Increasing usage of genomics in specialized or personalized medicines
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 Shortage of trained genomics professionals
    • 3.2.2.2 High costs of establishing genomic laboratories
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Future market trends
• 3.6 Porter's analysis
• 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Competitive analysis of major market players
• 4.4 Competitive positioning matrix
• 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Service Type, 2021-2034 ($ Mn)

• 5.1 Key trends
• 5.2 Next generation sequencing
• 5.3 Genotyping
• 5.4 Microarray
• 5.5 Sanger sequencing
• 5.6 Other services

Chapter 6 Market Estimates and Forecast, By Application, 2021-2034 ($ Mn)

• 6.1 Key trends
• 6.2 Research
• 6.3 Diagnostics

Chapter 7 Market Estimates and Forecast, By End Use, 2021-2034 ($ Mn)

• 7.1 Key trends
• 7.2 Research institutes
• 7.3 Diagnostic centers
• 7.4 Pharmaceutical and biotechnological companies
• 7.5 Contract research organization (CROs)
• 7.6 Other end use

Chapter 8 Market Estimates and Forecast, By Region, 2021-2034 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
  • 8.3.6 Netherlands
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 South Korea
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Argentina
• 8.6 Middle East and Africa
  • 8.6.1 South Africa
  • 8.6.2 Saudi Arabia
  • 8.6.3 UAE

Chapter 9 Company Profiles

• 9.1 23andMe
• 9.2 Agilent Technologies
• 9.3 BGI Genomics
• 9.4 Bio Rad Laboratories
• 9.5 Color Genomics
• 9.6 Danaher
• 9.7 Eurofins Scientific
• 9.8 F. Hoffmann-La Roche
• 9.9 GE Healthcare
• 9.10 GENEWIZ (Azenta)
• 9.11 Illumina
• 9.12 LGC
• 9.13 Macrogen
• 9.14 IQVIA
• 9.15 QIAGEN